Saturday, August 31, 2013

National CFIDS Foundation Awards New Research Grant to Scientist in Ireland

National CFIDS Foundation Awards New Research Grant to Scientist in Ireland
August 30, 2013

The National CFIDS Foundation, of Needham MA, is pleased to announce the funding
of a new research project that will further contribute to the understanding of CFIDS

Dr. Ciaran Morrison, Professor of Biochemistry with the Centre for Chromosome Biology
at NUI Galway, is the grant recipient of an award for $ 152,387 from the National CFIDS
Foundation. Dr. Morrison's research focuses mainly on cellular DNA damage response and chromosome abnormalities.

According to Alan Cocchetto, Medical Director, "Dr. Morrison's research is aimed at
increasing our fundamental understanding of the molecular mechanisms that underly
chromosome damage associated with CFIDS. This research will complement and extend
the SKY analysis testing and analysis that is n earing completion by Dr. Henry Heng at Wayne
State University."

Gail Kansky, President, stated "Dr. Heng has provided us with valuable insight into the
DNA damage that was found to be present in our patient cohort. Now, we will scientifically
push to better understand the resulting chromosomal damage and the basis for it via this
grant to Dr. Morrison. No other organization, be it public or private, has ever looked at
either quantifying or identifying the true nature of the chromosomal abnormalities associated
with this disease. We feel that this will add an important piece to the CFIDS puzzle."

The National CFIDS Foundation is one of the largest CFIDS organizations in the U.S.
The Foundation has no paid employees and all donations go to support CFIDS research.
To date, the National CFIDS Foundation has awarded $ 1.75 million dollars to scientists
from around the globe to advance medical knowledge of the disease. For additional
information, please cont act the National CFIDS Foundation at 781-449-3535.

Thursday, August 29, 2013

Media Center | Whittemore Peterson Institute for Neuro-Immune Disease


Dr. Kenny De Meirleir Web Seminars:

These web seminars are part of the project Wetenschap voor Patienten, or in English, Science for Patients. This project is a collaboration between Science Alliance and Dutch ME/cvs Vereniging ( There will be 20 web seminars with Dr. Kenny De Meirleir. Other ME/CFS scientists will follow. Not all seminars are available with English subtitles yet.

Is ME and/or CFS a disease?

Is it possible to diagnose ME/CFS?

Is ME a hereditary condition?

ME and sleep disorders

ME and pain

ME and Hormones

ME, the Immune System and several Viruses

ME and the Blood Circulation

ME and Gastrointestinal Problems

Parents reach out on allergy dangers after daughter's death

When someone tells you they're allergic to something, make a note of it.
No, my food allergies are not a joke.  No, I am not able to "just have a taste".  No, I'm not just saying I'm allergic to avoid things I don't like -- in fact, I'm allergic to something I love the taste of.
In fact, your best bet would be to avoid serving anything that includes any of the Top Ten food allergens.  Or at least label it if it includes nuts, soy, wheat, dairy, etc., so that those of us with allergies can stay away from it.

Wednesday, August 28, 2013

Today's big announcement from WPI

Source: Nevada Newsmakers
Date: August 27, 2013

Sam Shad:
Annette, you've just hired a new medical director. What's
that all about ?

Annette Whittemore:
That is very exciting news. We've just heard that he had his
medical licence. He is coming from Belgium with extensive
experience in ME and other chronic diseases. Dr. De Meirleir
is his name.

Too much medicine? Thyroid and CFS

Analysis: Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours

Tuesday, August 27, 2013 - 09:08

New imaging techniques are fuelling an epidemic in diagnosis and
treatment of thyroid cancers that are unlikely to ever progress
cause symptoms or death, warn experts on today.

New technologies such as ultrasound, CT and MRI scanning can detect
thyroid nodules as small as 2mm – many of these small nodules are
papillary thyroid cancers.

In the US, cases have tripled in the past 30 years - from 3.6 per
100,000 in 1973 to 11.6 per 100,000 in 2009 – making it one of the
fastest growing diagnoses. Yet the death rate from papillary thyroid
cancer has remained stable.

This expanding gap between incidence of thyroid cancer and deaths
suggests that low risk cancers are being overdiagnosed and
, argue Dr Juan Brito and colleagues at the Mayo Clinic in

This is exposing patients to unnecessary and harmful treatment that is
inconsistent with their prognosis, they warn, and they say both the
overdiagnosis and overtreatment of this form of cancer need to be
fully recognised.

The article is part of a series looking at the risks and harms of
overdiagnosis in a range of common conditions. The series, together
with the Preventing Overdiagnosis conference in September, are part of
the BMJ's Too Much Medicine campaign to help tackle the threat to
health and the waste of money caused by unnecessary care.

The authors say that unnecessary thyroidectomy (the surgical removal
of all or part of the thyroid gland) is costly and carries a risk of
complications such as low calcium levels and nerve injury. In the US,
the number of thyroidectomies for thyroid cancer has risen by 60% over
the past 10 years at an estimated cost of $416m (£270m; €316m).

Using radioactive iodine in patients with low risk thyroid cancer has
also increased from one in 300 patients to two in five patients
between 1973 and 2006, despite recommendations against using it, they

They acknowledge that inferring overdiagnosis of thyroid cancer has
limitations, but say that uncertainty about the benefits and harms of
immediate treatment for low risk papillary thyroid cancer "should spur
clinicians to engage patients in shared decision making … to ensure
treatment is consistent with the research evidence and patient goals."

They suggest a term that conveys favorable prognosis for low risk
thyroid cancers (microPapillary Lesions of Indolent Course or
microPLIC)) and makes it easier to give patients the choice of active
surveillance over immediate and often intensive treatment. And they
call for research to identify the appropriate care for these patients.


Free full text:

Thyroid cancer: zealous imaging has increased detection and treatment
of low risk tumours


Too Much Medicine

BMJ 2013; 347 doi: (Published 27
August 2013)
Cite this as: BMJ 2013;347:f4706

Juan P Brito, instructor of medicine12,
John C Morris, professor1,
Victor M Montori, professor12

Author Affiliations

Correspondence to: V M Montori [email protected]

Summary box

Clinical context—Thyroid cancer is the most common endocrine
malignancy and one of the fastest growing diagnoses

Diagnostic change—Introduction of neck ultrasonography into routine
endocrinological practice in the 1980s with guided biopsy in the late
1990s, plus increased use of computed tomography and magnetic
resonance imaging for other conditions

Rationale for change—New imaging methods allow the detection and
biopsy of thyroid nodules as small as 2 mm

Leap of faith—Patients with small papillary cancers will benefit from
their removal

Increase in disease—Worldwide increase in incidence of thyroid cancer
since the early 1980s but with considerable variation between
countries. In the US the incidence of thyroid cancer has increased
from 3.6 cases/100 000 population in 1973 to 11.6 cases/100 000 in
2009. Small papillary thyroid cancers, the most indolent form of
thyroid cancer, account for 90% of cases

Evidence of overdiagnosis—The expanding gap between the incidence of
thyroid cancer and stable death rates from papillary thyroid cancer
(0.5/100 000 in 1979 and 2009). Observational evidence shows that
small papillary thyroid cancers, which are a common autopsy finding,
may never progress to cause symptoms or death

Harms from overdiagnosis—Patients having thyroidectomy experience
physical complications, financial and psychosocial burdens, and need
lifelong thyroid replacement therapy

Limitations—Inference about overdiagnosis of thyroid cancer is based
on epidemiological and observational evidence

Conclusion – The incidence of small and indolent thyroid cancer is
increasing, exposing patients to treatments inconsistent with their
prognosis. We suggest a term that conveys the favourable prognosis for
low risk thyroid cancers (micropapillary lesions of indolent course or
microPLICs) and call for research to identify the appropriate care for
these patients

Tuesday, August 27, 2013

To the Author of the Anonymous Note Left on My Car Window

96% of disabilities are invisible.  Just because the person doesn't use a mobility assistive device doesn't mean they're not disabled. 
I have problems with my shoulders/arms/wrists/hands.  If I use crutches, walker or a cane, that causes MORE problems with my upper extremities.  I made the considered decision to NOT use a mobility assistive device in order to preserve my ability to use my hands.  Thanks, but I'd rather be able to wipe my own butt at the end of the day, even if this makes walking somewhat more problematic.
The fact that I'm managing WITHOUT a cane means even more reason why I should not be criticized when I get out of a car parked in a handicap space.

Free Webinar: Why Cholesterol Isn't the Enemy, By Dr. Stephen Sinatra

Free Webinar: Why Cholesterol Isn't the Enemy, By Dr. Stephen Sinatra

Dear Readers,

As I have noted in the past, I find that cholesterol medications (called statins) can markedly worsen fibromyalgia symptoms and biochemistry. I also believe that treating with these medications simply for high cholesterol in the absence of known heart disease is a mistake. Many of you have been caught in a conflict between your well-meaning family physician saying that you need to take these medications, and your fibromyalgia experts who recommend that you not. The exception? For those with known heart disease, statins can be lifesaving and I do recommend them.

On September 19, one of my favorite heart specials and friend Dr. Stephen Sinatra will discuss the truth about cholesterol medications in a free webinar. I whole-heartedly recommend that you register for this to hear what he has to say.

Webinar Details

When: September 19, 2013, 2:00 PM EDT
Click here for free registration.

Dr. Sinatra, a highly credentialed integrative cardiologist, has long been concerned that many people needlessly worry about their cholesterol levels while failing to recognize the real dangers to their heart health.

The goal of Dr. Sinatra's webinar is to debunk the cholesterol myth — and to help us all understand the true causes of heart disease and the positive steps we can take toward better-lasting heart health.

In his webinar, Dr. Sinatra will cover:

  • What the latest medical research shows about high cholesterol and heart health.
  • The real dangers that lead to heart disease: sugars and trans fats.
  • The pros and cons of taking statin drugs.

As a fellow health seeker, I hope that you will join me in hearing what Dr. Sinatra has to say about this very important and always timely health topic.

Click here for free registration.

Love & blessings,

Dr. T

Autism Risk Linked to Maternal Thyroid Dysfunction

Here's a more accessible version:
"a study of more than 4,000 Dutch mothers and their children, and it supports a growing view that autism spectrum disorders can be caused by a lack of maternal thyroid hormone, which past studies have shown is crucial to the migration of fetal brain cells during embryo development.

"It is increasingly apparent to us that autism is caused by environmental factors in most cases, not by genetics," said lead author Gustavo Román, M.D., a neurologist and neuroepidemiologist who directs the Nantz National Alzheimer Center. "That gives me hope that prevention is possible."


Since CFS patients often have thyroid problems, this is something to take into account when considering pregnancy.

Personally, I can barely take care of myself; I would not be able to provide adequate care for a special-needs child.